Format

Send to

Choose Destination
Expert Opin Pharmacother. 2010 Dec;11(17):2933-8. doi: 10.1517/14656566.2010.529432.

Colchicine for the treatment of gout.

Author information

1
Fédération de Rhumatologie, Hôpital Lariboisière, Paris, France. pascal.richette@lrb.aphp.fr

Abstract

IMPORTANCE OF THE FIELD:

Colchicine, used for a long period in gout, was approved for the first time in 2009 by the FDA for the prophylaxis and the treatment of acute attack, on the basis of a pivotal trial that showed the efficacy in the very short term - that is 24 h of a well-tolerated, low-dose regimen of Colcrys (colchicine, URL Pharma, Philadelphia, USA) to reduce pain in patients with acute gout - when given early.

AREAS COVERED IN THIS REVIEW:

We searched the Cochrane Library and Medline for articles published in English from January 2000 to August 2010 using the following search terms: colchicine, gout, efficacy, toxicity, drug interaction. Some information from the FDA was also included because it provides comprehensive overviews that are within the scope of this review.

WHAT THE READER WILL GAIN:

Colchicine is a drug with a narrow therapeutic-toxicity window and with an important variability in tolerance between subjects. This paper reviews recent important findings on its pharmacology and efficacy which will allow a better use of this drug for the treatment of acute attack of gout. Also, pharmacokinetic, drug interaction and toxicity of colchicine are discussed.

TAKE HOME MESSAGE:

Low-dose colchicine (1.8 mg over 1 h) taken as early as possible ('pills in the pocket') is effective in reducing pain and is well tolerated in patients with acute gout.

PMID:
21050036
DOI:
10.1517/14656566.2010.529432
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center